Non-ST-Segment Elevation Acute Coronary Syndrome: The Last Nail in the Coffin of Pre-Treatment
- PMID: 33213724
- DOI: 10.1016/j.jacc.2020.10.010
Non-ST-Segment Elevation Acute Coronary Syndrome: The Last Nail in the Coffin of Pre-Treatment
Keywords: acute coronary syndrome; myocardial infarction; percutaneous coronary intervention; prasugrel; pretreatment; ticagrelor.
Conflict of interest statement
Author Relationship With Industry Dr. Montalescot has received research or educational grants to the institution or consulting/lecture fees from Abbott, AIM Group, Amgen, Actelion, American College of Cardiology Foundation, AstraZeneca, Axis-Santé, Bayer, Boston Scientific, Bristol Myers Squibb, Beth Israel Deaconess Medical, Brigham Women’s Hospital, Fréquence Médicale, ICOM, Idorsia, Elsevier, Fédération Française de Cardiologie, Fréquence Médicale, ICAN, Lead-Up, Menarini, Medtronic, Merck Sharp and Dohme, Novo Nordisk, Pfizer, Quantum Genomics, Sanofi-Aventis, SCOR global life, Servier, and WebMD.
Comment on
-
Timing of Oral P2Y12 Inhibitor Administration in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome.J Am Coll Cardiol. 2020 Nov 24;76(21):2450-2459. doi: 10.1016/j.jacc.2020.08.053. Epub 2020 Aug 31. J Am Coll Cardiol. 2020. PMID: 32882390 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
